8-K Announcements
6Material company update
Jun 17, 2026·SEC
Material company update
Jun 15, 2026·SEC
Material company update
Jun 9, 2026·SEC
VistaGen Therapeutics, Inc.(VTGN)Earnings, Financials & Key Ratios
VTGN•NASDAQ
$0.62
Price updated Jun 25, 2026
AboutVistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.Show more
- Revenue$1M+161.1%
- EBITDA-$71M-29.0%
- Net Income-$70M-35.5%
- EPS (Diluted)-1.83-9.6%
- Gross Margin100%
- EBITDA Margin-5625.93%+50.6%
- Operating Margin-5683.69%+50.6%
- Net Margin-5491.33%+48.1%
- ROE-131.59%-136.3%
VTGN Price & Volume
VistaGen Therapeutics, Inc. (VTGN) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Licensing Revenue Growth
Investment Thesis • Updated 2026Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial binary outcome
"VistaGen Therapeutics remains in a high-risk, clinical-stage development phase characterized by persistent net losses and a reliance on non-recurring licensing milestones to fund operations. The company's R&D intensity, evidenced by $13.1 million in quarterly expenditures as of 2026Q4, continues to significantly outstrip its limited revenue generation, creating a structural dependency on external capital. Investors should monitor the company's ability to reach clinical milestones before its current cash reserves, which have declined to $30.8 million, necessitate further dilutive equity financing."
Verdict Logic
the company's rapid contraction of total assets from $131.1 million in 2024Q3 to $48.6 million in 2026Q4 suggests significant long-term solvency risks without a clear path to self-sustaining commercial revenue.
VTGN Growth Metrics
VistaGen Therapeutics, Inc. (VTGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years3.1%
3 Years-
TTM161.32%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-35.53%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-11.98%
Return on Capital
10 Years-254.87%
5 Years-87.2%
3 Years-80.64%
Last Year-134.19%
VTGN Recent Earnings
VistaGen Therapeutics, Inc. (VTGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q3 2026Latest
Jun 15, 2026Metric
Actual
Est
EPS
$0.37-9.9%
$0.34
Rev
$464,000+16.0%
$399,900
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.45+11.8%
$0.51
Rev
$303,000-16.9%
$364,433
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.54-5.9%
$0.51
Rev
$258,000+77.0%
$145,800
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.47+0.0%
$0.47
Rev
$244,000+13.1%
$215,670
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 15, 2026 | $0.37vs $0.34-9.9% | $464,000vs $399,900+16.0% |
| Q1 2026 | Feb 12, 2026 | $0.45vs $0.51+11.8% | $303,000vs $364,433-16.9% |
| Q4 2025 | Nov 13, 2025 | $0.54vs $0.51-5.9% | $258,000vs $145,800+77.0% |
| Q3 2025 | Aug 7, 2025 | $0.47vs $0.47+0.0% | $244,000vs $215,670+13.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for VistaGen Therapeutics, Inc. (VTGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.62 | $20.21M | -0.34 | 161.11% | -5491.33% | -131.59% | — | |
| $327.99 | $9.47B | -24.33 | -100% | — | -43.02% | — | |
| $4.98 | $384.92M | 31.13 | -4.9% | 3.16% | 12.53% | — | |
| $237.33 | $12.21B | -64.49 | 65.55% | -26.59% | -260.01% | — | |
| $23.35 | $1.72B | 7.08 | 18.52% | 118.91% | 47.59% | — | |
| $15.34 | $1.62B | -2.24 | — | — | -866.46% | — |
Compare VTGN vs Peers
VistaGen Therapeutics, Inc. (VTGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VTGN SEC Filings & Documents
VistaGen Therapeutics, Inc. (VTGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VTGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VTGN Frequently Asked Questions
VistaGen Therapeutics, Inc. (VTGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is VistaGen Therapeutics, Inc.'s revenue?
VistaGen Therapeutics, Inc. (VTGN) reported $1.3M in revenue for fiscal year 2026.
How fast is VistaGen Therapeutics, Inc. growing?
VistaGen Therapeutics, Inc. (VTGN) grew revenue by 161.1% over the past year. This is strong growth.
Is VTGN profitable?
VistaGen Therapeutics, Inc. (VTGN) reported a net loss of $69.7M for fiscal year 2026.
Dividend & Returns
What is VTGN's return on equity?
VistaGen Therapeutics, Inc. (VTGN) has a return on equity (ROE) of -131.6%. Negative ROE indicates the company is unprofitable.
What is VistaGen Therapeutics, Inc.'s free cash flow?
VistaGen Therapeutics, Inc. (VTGN) had negative free cash flow of $66.6M in fiscal year 2026, likely due to heavy capital investments.